PKN Stock Chart & Stats
€76.22
-€2.15(-1.91%)
At close: 4:00 PM EST
€76.22
-€2.15(-1.91%)
Day’s Range― - ―
52-Week Range€69.64 - €99.44
Previous CloseN/A
Volume0.00
Average Volume (3M)2.00
Market Cap
€11.06B
Enterprise Value€13.40B
Total Cash (Recent Filing)€860.32M
Total Debt (Recent Filing)€3.35B
Price to Earnings (P/E)53.7
Beta0.55
Next Earnings
Aug 03, 2026EPS Estimate
1.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.10
Shares Outstanding111,559,780
10 Day Avg. Volume0
30 Day Avg. Volume2
Financial Highlights & Ratios
PEG Ratio-3.41
Price to Book (P/B)1.52
Price to Sales (P/S)3.85
P/FCF Ratio21.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€93.71Price Target Upside22.95% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)4.6
Revenue Forecast (FY)€2.49B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables & Software RevenueRevvity’s mix of capital instruments plus consumables, reagents and growing software ARR generates recurring revenue and installed-base stickiness. Robust SaaS/ARR growth (~30–40% cited) supports higher margin, more predictable cash flows and stronger customer retention over multi-year horizons.
Strong Absolute Cash Generation And Conservative Debt ProfileHigh absolute FCF and solid operating cash flow give Revvity durable internal funding for R&D, M&A, and buybacks. Manageable leverage (net debt/EBITDA ~2.8x) and largely fixed-rate debt reduce refinancing risk and preserve strategic flexibility across economic cycles.
Portfolio Optimization To Improve Margins And GrowthThe planned divestiture of the underperforming China immunodiagnostics unit is a structural move to sharpen the portfolio. Removing a low-growth, policy-impacted business should improve pro forma organic growth and operating margins, enabling management to allocate capital to higher-return areas long term.
Bears Say
Earnings Volatility And Low ReturnsRevvity’s ROE (~3.3% TTM) and past earnings volatility (including a 2023 loss) indicate the company has struggled to convert scale into consistently strong returns. Persistently low ROE limits shareholder value creation and raises the bar for management to demonstrate durable improvements in profitability and capital efficiency.
Weakening Cash-conversion TrendsDespite high absolute FCF, recent declines in cash-conversion ratios and negative FCF growth signal working-capital or operational timing pressures. Deteriorating conversion undermines the reliability of cash generation for capex, acquisitions, or buybacks and can amplify stress during demand slowdowns.
Divestiture Causes Near-term Revenue, EPS Headwind And Timing RiskWhile strategically sensible, the planned China sale creates a tangible near-term hit to reported revenue and adjusted EPS and leaves proceeds and benefits contingent on a 2027 close. The LOI-stage transaction adds execution and regulatory risk, creating uncertainty around cash and earnings realization in the medium term.
Revvity News
PKN FAQ
What was Revvity, Inc.’s price range in the past 12 months?
Revvity, Inc. lowest stock price was €69.64 and its highest was €99.44 in the past 12 months.
What is Revvity, Inc.’s market cap?
Revvity, Inc.’s market cap is €11.06B.
When is Revvity, Inc.’s upcoming earnings report date?
Revvity, Inc.’s upcoming earnings report date is Aug 03, 2026 which is in 32 days.
How were Revvity, Inc.’s earnings last quarter?
Revvity, Inc. released its earnings results on May 05, 2026. The company reported €0.914 earnings per share for the quarter, beating the consensus estimate of €0.893 by €0.021.
Is Revvity, Inc. overvalued?
According to Wall Street analysts Revvity, Inc.’s price is currently Undervalued.
Does Revvity, Inc. pay dividends?
Revvity, Inc. does not currently pay dividends.
What is Revvity, Inc.’s EPS estimate?
Revvity, Inc.’s EPS estimate is 1.06.
How many shares outstanding does Revvity, Inc. have?
Revvity, Inc. has 111,559,780 shares outstanding.
What happened to Revvity, Inc.’s price movement after its last earnings report?
Revvity, Inc. reported an EPS of €0.914 in its last earnings report, beating expectations of €0.893. Following the earnings report the stock price went up 2.447%.
Which hedge fund is a major shareholder of Revvity, Inc.?
Currently, no hedge funds are holding shares in DE:PKN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Revvity Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€93.71 (22.95% Upside)
€93.71 (22.95% Upside)
Blogger Sentiment
Bullish
DE:PKN Sentiment 70%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
14.27%
12-Months-Change
Fundamentals
Return on Equity
3.28%
Trailing 12-Months
Asset Growth
-2.95%
Trailing 12-Months
Company Description
Revvity, Inc.
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.
PKN Company Deck
PKN Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a generally positive tone driven by a better-than-expected Q1 (organic growth, margin and EPS beats), strong cash conversion, healthy software ARR trends, and a strategic decision to divest a underperforming China diagnostics business that should improve longer-term margins and growth. Near-term cautions include China market weakness, Q2 software cadence volatility, a ~$0.15 EPS headwind in 2026 from the divestiture (with proceeds not realized until 2027), and reduced FX tailwinds. Management emphasized operational cost initiatives and expected margin expansion into the second half of the year and into 2027, supporting an upbeat long-term outlook despite the identified near-term risks.View all DE:PKN earnings summariesPKN Revenue Breakdown
50.11% Life sciences
49.89% Diagnostics
PKN Stock 12 Month Forecast
Average Price Target
€93.71
▲(22.95% Upside)
Technical Analysis
Options Prices
Currently, No data available
---